Skip to main content
. 2013 Feb 21;76(5):680–688. doi: 10.1111/bcp.12095

Figure 3.

Figure 3

Second study: median plasma gastrin concentrations (ng l−1) on days A) 1 and B) 14 of netazepide 5 mg (n = 11) and 25 mg (n = 12) once daily. Placebo data (n = 12) from Day 7 of the first study. Netazepide 5 mg (Inline graphic), netazepide 25 mg (Inline graphic) and placebo (Inline graphic)